Aerie Pharmaceuticals Inc (AERI) Receives $70.17 Consensus Price Target from Analysts

Aerie Pharmaceuticals Inc (NASDAQ:AERI) has received an average rating of “Buy” from the sixteen research firms that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have issued a buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $70.17.

AERI has been the subject of a number of analyst reports. Mizuho reaffirmed a “buy” rating and issued a $70.00 price target on shares of Aerie Pharmaceuticals in a report on Wednesday, October 25th. Zacks Investment Research raised Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 24th. Cantor Fitzgerald set a $69.00 price target on Aerie Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, November 16th. Finally, Canaccord Genuity set a $73.00 price target on Aerie Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, December 18th.

Aerie Pharmaceuticals (AERI) traded up $1.40 during midday trading on Tuesday, reaching $59.30. The company had a trading volume of 504,100 shares, compared to its average volume of 293,262. The firm has a market cap of $2,180.00, a PE ratio of -17.70 and a beta of 1.11. Aerie Pharmaceuticals has a 12 month low of $38.14 and a 12 month high of $66.60. The company has a quick ratio of 15.24, a current ratio of 15.24 and a debt-to-equity ratio of 0.78.

Aerie Pharmaceuticals (NASDAQ:AERI) last released its quarterly earnings results on Wednesday, November 8th. The company reported ($0.89) earnings per share for the quarter. equities analysts anticipate that Aerie Pharmaceuticals will post -3.94 EPS for the current fiscal year.

Several institutional investors have recently made changes to their positions in the business. Ameritas Investment Partners Inc. raised its holdings in shares of Aerie Pharmaceuticals by 11.5% during the second quarter. Ameritas Investment Partners Inc. now owns 2,665 shares of the company’s stock valued at $140,000 after acquiring an additional 275 shares during the last quarter. Legal & General Group Plc raised its holdings in shares of Aerie Pharmaceuticals by 7.4% during the second quarter. Legal & General Group Plc now owns 7,534 shares of the company’s stock valued at $396,000 after acquiring an additional 519 shares during the last quarter. Bamco Inc. NY grew its position in shares of Aerie Pharmaceuticals by 13.4% in the second quarter. Bamco Inc. NY now owns 5,511 shares of the company’s stock valued at $290,000 after purchasing an additional 653 shares in the last quarter. Chartwell Investment Partners LLC grew its position in shares of Aerie Pharmaceuticals by 3.2% in the third quarter. Chartwell Investment Partners LLC now owns 25,591 shares of the company’s stock valued at $1,243,000 after purchasing an additional 791 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in shares of Aerie Pharmaceuticals by 5.5% in the second quarter. The Manufacturers Life Insurance Company now owns 23,501 shares of the company’s stock valued at $1,235,000 after purchasing an additional 1,235 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3146468/aerie-pharmaceuticals-inc-aeri-receives-70-17-consensus-price-target-from-analysts.html.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.